TCIM
TEVA icon

TIAA CREF Investment Management’s Teva Pharmaceuticals TEVA Stock Holding History

TIAA CREF Investment Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$103M Buy
6,586,071
+550,496
+9% +$9.71M 0.07% 249
2018
Q4 		$93.1M Sell
6,035,575
-299,874
-5% -$6.15M 0.07% 256
2018
Q3 		$136M Buy
6,335,449
+264,693
+4% +$6.15M 0.09% 212
2018
Q2 		$148M Buy
6,070,756
+823,633
+16% +$16.8M 0.1% 198
2018
Q1 		$89.7M Buy
5,247,123
+3,859,347
+278% +$75.4M 0.06% 298
2017
Q4 		$26.3M Buy
1,387,776
+226,110
+19% +$3.4M 0.02% 664
2017
Q3 		$20.4M Buy
1,161,666
+495,592
+74% +$11.2M 0.01% 753
2017
Q2 		$22.1M Buy
666,074
+33,938
+5% +$1.05M 0.02% 706
2017
Q1 		$20.3M Sell
632,136
-384,461
-38% -$13.1M 0.01% 739
2016
Q4 		$36.9M Buy
1,016,597
+578,826
+132% +$23.1M 0.03% 525
2016
Q3 		$20.1K Sell
437,771
-1,637,576
-79% -$85.4M 0.01% 777
2016
Q2 		$104M Sell
2,075,347
-409,949
-16% -$21.8M 0.08% 258
2016
Q1 		$133M Buy
2,485,296
+843,358
+51% +$49.5M 0.1% 197
2015
Q4 		$108M Buy
1,641,938
+1,163,133
+243% +$71.9M 0.08% 249
2015
Q3 		$27M Buy
478,805
+108,800
+29% +$7.05M 0.02% 640
2015
Q2 		$21.9M Hold
370,005
– – 0.02% 758
2015
Q1 		$23.1M Sell
370,005
-34,000
-8% -$1.98M 0.02% 727
2014
Q4 		$23.2M Hold
404,005
– – 0.02% 711
2014
Q3 		$21.7M Buy
404,005
+85,326
+27% +$4.52M 0.02% 737
2014
Q2 		$16.7M Sell
318,679
-26,000
-8% -$1.33M 0.01% 858
2014
Q1 		$18.2M Buy
344,679
+60,000
+21% +$2.77M 0.01% 826
2013
Q4 		$11.4M Sell
284,679
-619,986
-69% -$24.4M 0.01% 1068
2013
Q3 		$34.2M Sell
904,665
-305,828
-25% -$11.9M 0.03% 569
2013
Q2 		$47.5M Buy
+1,210,493
New +$47.1M 0.04% 461

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TIAA CREF Investment Management's TEVA Position: Q1 2019 in Review

TIAA CREF Investment Management increased its Teva Pharmaceuticals (TEVA) stake by 9.1% in Q1 2019, buying an estimated $9.71M and bringing the position to 6,586,071 shares worth $103M. The position accounts for 0.07% of the portfolio, ranked #249.

TIAA CREF Investment Management first reported a position in TEVA in Q2 2013 and has held it in 24 quarters since. The position peaked at $148M in Q2 2018. 522 funds tracked by Wall St. Rank hold TEVA as of Q1 2019.

  • TIAA CREF Investment Management held 6,586,071 shares of Teva Pharmaceuticals worth $103M as of Q1 2019.
  • TIAA CREF Investment Management bought 550,496 Teva Pharmaceuticals shares in Q1 2019, an estimated $9.71M.
  • Teva Pharmaceuticals made up 0.07% of TIAA CREF Investment Management's portfolio in Q1 2019, its #249 holding.
  • TIAA CREF Investment Management first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 24 quarters since.
  • TIAA CREF Investment Management's Teva Pharmaceuticals position peaked at $148M in Q2 2018.
  • 522 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.